011 The british childhood visual impairment and blindness study (BCVIS2): 1-year outcomes. (December 2018)

• Record Type: Journal Article
• Authors: Teoh, L; Rahi, J; Solebo, A; Cumberland, P
• Is Part Of: Archives of disease in childhood. Volume 103(2018)Supplement 2
• Page Start: A5
• Page End: A5
• Publication Date: 2018-12
• Subjects: Children -- Diseases -- Periodicals; Infants -- Diseases -- Periodicals; 618.920005
• DOI: 10.1136/goshabs.11
• Languages: English
• ISSNs: 0003-9888

Abstract

Abstract : Introduction: BCVIS2 aims to provide, for the first time, nationally representative data on the incidence, causes, risk factors, management and treatment of all-cause, full spectrum childhood visual impairment. Methods: All children newly diagnosed as VI or SVI/BL using the WHO classification (VI: 0.5–1.0 LogMAR, SVI: 1.01–1.30 LogMAR and BL:<1.30 LogMAR in the better eye) were identified in the U.K. within a 1 year period. Dual source active surveillance schemes was carried out through the British Ophthalmological Surveillance Unit and the British Paediatric Surveillance Unit. Great Ormond Street Hospital was a key reporting centre that showed excellent engagement across ophthalmology, neuro-disability and endocrinology departments. Results: To date, of the 833 cases reported, 770 have confirmed visual disability comprising 247 VI and 336 SVI/BL cases. 12% were lost to follow up, and 6% died within 1 year (26 children SVI, 1 child VI). Analysis of SVI/BL cases (n=464) shows that – children of low birth weight, of ethnic minority origin, or from the most socially deprived group are over-represented – most children (74%) have additional major non-ophthalmic disorders – disorders of the visual pathway/cortex remain predominant with increased contribution of 62%. Children with VI (n=308), in comparison to SVI/BL are: – diagnosed later (42% vs 57% diagnosed aged <1 year) – less likely to have additional non-ophthalmic conditions (56% vs 86%) – more likely to have a retinal disorder such as retinal dystrophy (23% vs 11%) or oculocutaneous albinism (13% vs 4%). Discussion/conclusion: Outcomes at 1 year will be presented for the entire BCVIS2 cohort (n=770) including treatment and management of key disorders. National age-specific incidence rates for SVI/BL will be presented and compared to that from the first study of childhood blindness.